Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 17 January, 2020

BB BIOTECH AG

BB Biotech AG closes the 2019 fiscal year with a profit

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Preliminary Results
BB Biotech AG closes the 2019 fiscal year with a profit

17-Jan-2020 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Media Release, January 17, 2020

BB Biotech AG closes the 2019 fiscal year with a profit

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its fiscal year 2019.

BB Biotech AG closed its fiscal year 2019 with a profit of approximately CHF 677 million, based on its preliminary unaudited consolidated results (CHF 471 million loss in the previous year).

As an investment company, the results reflect the performance of the stocks BB Biotech AG holds in its investment portfolio.

The publication of all relevant portfolio data will take place on January 17, 2020 at 7:00 am and the complete annual report will be published on February 21, 2020.


For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, [email protected]

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.


17-Jan-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: [email protected]
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID: 955315

 
End of Announcement DGAP News Service

955315  17-Jan-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=955315&application_name=news&site_id=financialexpress

a d v e r t i s e m e n t